Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026

Same author

TRAC in vivo: culmination of CAR and vector engineering.

Cell research·2026

Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026

Same author

Dual CAR-T cell therapy targeting CD19 and BCMA as a novel opportunity for immune reset in systemic lupus erythematosus.

Cellular & molecular immunology·2026

Same author

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

bioRxiv : the preprint server for biology·2026

Same author

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

Cell·2026

Search research articles

Related Experiment Video

Updated: Mar 1, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Therapeutic T cell engineering.

Michel Sadelain¹, Isabelle Rivière¹, Stanley Riddell²

¹Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

|May 26, 2017

Summary

This summary is machine-generated.

Genetically engineered T cells, using Chimaeric Antigen Receptors (CARs), show promise for treating cancer. Further research aims to expand their use in various diseases by addressing challenges like antigen targeting and tumor microenvironments.

More Related Videos

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Mar 1, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Genetically engineered T cells represent a significant advancement in cancer therapy.
Chimaeric Antigen Receptors (CARs) are synthetic receptors that redirect T cell activity.
CD19-targeted CARs have shown high efficacy in B cell malignancies.

Purpose of the Study:

To review the potential and challenges of T cell-based therapies.
To highlight advances in T cell engineering and manufacturing.
To explore future applications beyond cancer treatment.

Main Methods:

Review of current literature on CAR T cell therapy.
Analysis of successes in B cell malignancies.
Discussion of challenges in solid tumors and other diseases.

Main Results:

CAR T cells, particularly those targeting CD19, are effective against B cell cancers.
Significant hurdles remain, including antigen identification, tumor microenvironment modulation, toxicity, and antigen escape.
Advances in T cell selection, genetic engineering, and manufacturing are crucial.

Conclusions:

Engineered T cell therapies hold great potential for various cancers.
Overcoming current limitations is key to broader clinical application.
Future applications may extend to infectious diseases and autoimmune disorders.